How Stress Alters Opioid Drug Effects

NCT ID: NCT06485817

Last Updated: 2024-07-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-15

Study Completion Date

2022-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of the study is to test the hypothesis that opioid drug effects vary as a function of pre-drug affective state. Specifically, it is hypothesized that social stress induction enhances opioid drug wanting compared a non-stress control condition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Healthy participants complete four experiment sessions in a placebo-controlled, double-blind, randomized repeated-measures psychopharmacological study. Participants completed four combinations of pre-drug state induction (social stress or no-stress) and drug (intravenous oxycodone or saline).

Temporary and reversible social stress is induced using the Repeatable Social Stress Test (ReSST) which enables repeated administrations of stress-inductions. Across four sessions participants experience two carefully tailored tasks to provoke the experience of social evaluative threat and two non-stressful control tasks.

After each state inductions, participants receive an injection of opioid drug or saline. After a drug absorption phase and viewing of a state reinstatement video designed to evoke a mild form of social evaluative threat participants perform a drug-self-administration test to determine the potency of a second dose.

Self-reported affect, mental and physiological state and drug effects are assessed throughout the session.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Motivation Drug Effect Stress Reaction Misuse, Opioid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Cross-over 2\*2 design Drug (i.v. oxycodone/placebo) State induction (stress/control)
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
Experimenters, care providers (nurses/physicians) and participants were blinded to both the stress induction condition and the drug in all sessions.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo_Control

Control state induction:

Participants answer simple questions about their color or music preferences in a hybrid (zoom-lab) session with a friendly experimenter (The Repeatable Social Stress Test (ReSST) control conditions).

Drug administration:

A sampling dose of intravenous (i.v.) saline administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of saline (0-100% of the initial sampling dose) determined by a behavioral self-administration task.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Pure saline was administered as the placebo condition.

Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.

The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.

Control State Induction

Intervention Type BEHAVIORAL

Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.

Oxycodone_Control

Control state induction:

Participants answer simple questions about their color or music preferences in a hybrid (zoom-lab) session with a friendly experimenter. (The Repeatable Social Stress Test (ReSST) control conditions).

Drug administration:

A sampling dose of i.v. oxycodone administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of oxycodone (0-100% of the initial sampling dose) determined by a behavioral self-administration task.

Group Type ACTIVE_COMPARATOR

Oxycodone

Intervention Type DRUG

3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.

Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.

The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.

Control State Induction

Intervention Type BEHAVIORAL

Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.

Placebo_Stress

State induction: Stress The Repeatable Social Stress Test (ReSST) was used to induce psychosocial stress (mock job talk in stress session 1 and singing task in stress session 2).

Drug administration:

A sampling dose of i.v. saline administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of saline (0-100% of the initial sampling dose) determined by a behavioral self-administration task.

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type DRUG

Pure saline was administered as the placebo condition.

Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.

The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.

Stress State Induction

Intervention Type BEHAVIORAL

ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).

The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting.

Oxycodone_Stress

State induction: Stress ReSST was used to induce psychosocial stress (mock job talk in stress session 1 and singing task in stress session 2).

Drug administration:

A sampling dose of i.v. oxycodone administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of oxycodone (0-100% of the initial sampling dose) determined by a behavioral self-administration task.

Group Type EXPERIMENTAL

Oxycodone

Intervention Type DRUG

3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.

Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.

The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.

Stress State Induction

Intervention Type BEHAVIORAL

ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).

The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxycodone

3.1mg oxycodone/70 kg body weight was administered as the main drug intervention.

Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.

The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.

Intervention Type DRUG

Placebo

Pure saline was administered as the placebo condition.

Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone.

The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later.

Intervention Type DRUG

Stress State Induction

ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST).

The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting.

Intervention Type BEHAVIORAL

Control State Induction

Two different control tasks matched to the stress conditions on key parameters outlined in the protocol.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Saline ReSST (Repeatable Social Stress Test): Stress ReSST (Repeatable Social Stress Test): Control

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mentally and physically healthy
* Body mass index (BMI) in the healthy range (18.5 \< BMI \< 30)
* Normal or corrected vision
* Had received an opioid drug at least once in their lifetime (to ensure no severe adverse or allergic reactions).

Exclusion Criteria

* Any significant physical health problem (e.g., heart, lung, kidney, liver, and other conditions)
* Current or past substance use problems
* Current mental health problems
* Past mental health problems beyond mild episodic anxiety or depression
* Social anxiety or fear of public speaking
* Past or current chronic pain
* Pregnancy or breastfeeding
* Recent use of any contraindicating medications
* Prior difficulty in providing blood samples.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oslo University Hospital

OTHER

Sponsor Role collaborator

Linkoeping University

OTHER_GOV

Sponsor Role collaborator

University of Oslo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marie Eikemo

Co-Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Siri Leknes, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Oslo

Marie Eikemo, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Oslo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Oslo

Oslo, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Analytic Code

Project directory where study relevant documentation can be found and data will be uploaded.

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://osf.io/bcxv8/

Time locked preregistration prior to data collection

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

https://osf.io/bcxv8

Identifier Type: OTHER

Identifier Source: secondary_id

802885

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Influence of Medication on Functional Connectivity
NCT03612713 COMPLETED EARLY_PHASE1
The Human Stress Response in a Simulated ED Setting
NCT04317482 ACTIVE_NOT_RECRUITING NA
Oxytocin and Social Behavior Over the Lifespan
NCT00914953 COMPLETED EARLY_PHASE1
The Discriminative Effects of Tramadol in Humans
NCT00499746 COMPLETED PHASE1/PHASE2